Drug intelligence / Profile preview

Lucenex

Development stage: Phase 2
Lead developer: Halucenex Life Sciences
Modality: Small Molecules
Administration: Oral

Overview

**Lucenex** is a branded synthetic psilocybin developed by Halucenex Life Sciences as a psychedelic therapy for post-traumatic stress disorder (PTSD). It is a small molecule psychedelic compound designed for therapeutic use in mental health disorders, with early Phase II clinical trial results reported as promising. Halucenex has pursued regulatory pathways including TGA registration in Australia for PTSD treatment, positioning it as an emerging psychedelic medicine in the mental health space.[8][10][14]

Brand names: Lucenex

Targets

HTR2A (Serotonin receptor 5-HT2A)

Beyond the preview

Go deeper on Lucenex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lucenex.

Explore the full profile